journal article Mar 01, 2024

Saikosaponin D mitigate pilocarpine‐induced astrocyte injury by regulating the NLRP3/caspase‐1 signaling pathway

View at Publisher Save 10.1111/cbdd.14481
Abstract
AbstractStudies have shown that saikosaponin D (SSD) has favorable neurotherapeutic effects. Therefore, the objective of this study was to explore the efficacy and possible molecular mechanisms of SSD on pilocarpine (PP)‐induced astrocyte injury. Primary astrocytes were isolated from juvenile rats and identified using immunofluorescence. The cells were treated with PP and/or SSD for 6 h and 12 h, respectively, followed by measurement of their viability through 3‐(4,5‐dimethylthiazol)‐2,5‐diphenyl‐tetrazolium bromide (MTT) assay. Next, quantitative real‐time polymerase chain reaction (qRT‐PCR) was used to measure the expression levels of Glial fibrillary acidic protein (GFAP), C3, S100 calcium binding protein A10 (S100a10), pentraxin 3 (Ptx3), toll‐like receptor 4 (TLR4), and RAG in astrocytes after different treatments. Enzyme‐linked immunosorbent assay and biochemical tests were utilized to evaluate the level of inflammatory factors [interleukin (IL)‐1β, IL‐6, and tumor necrosis factor alpha (TNF‐α)] secreted by cells and the content of oxidative stress‐related factors (malondialdehyde [MDA] and glutathione [GSH]) or enzyme activity (catalase [CAT] and glutathione peroxidase [GPX]) in cells. The JC‐1 mitochondrial membrane potential (MMP) fluorescence probe was used to measure the MMP in astrocytes. Additionally, western blot was applied to test the expression of proteins related to the nod‐like receptor protein 3 (NLRP3)/caspase‐1 signaling pathway. PP treatment (1 mM) induced cell injury by significantly reducing the viability of astrocytes and expression of cellular markers. SSD treatment (4 μM) had no toxicity to astrocytes. Besides, SSD (4 μM) treatment could significantly up‐regulate the cell viability and marker expression of PP‐induced astrocytes. Furthermore, SSD could be employed to inhibit inflammation (reduce IL‐1β, IL‐6, and TNF‐α levels) and oxidative stress (decrease MDA level, elevate GSH level, the activity of CAT and GPX), and ameliorate mitochondrial dysfunction (upregulate JC‐1 ratio) in PP‐induced astrocytes. Moreover, further mechanism exploration revealed that SSD treatment significantly reduced the activity of the NLRP3/caspase‐1 signaling pathway activated by PP induction. SSD increased cell viability, inhibited inflammation and oxidative stress response, and ameliorated mitochondrial dysfunction in PP‐induced astrocyte injury model, thus playing a neuroprotective role. The mechanism of SSD may be related to the inhibition of the NLRP3/caspase‐1 inflammasome.
Topics

No keywords indexed for this article. Browse by subject →

References
45
[17]
Jabbari Azad F. "Association between cytokine production and disease severity in Alzheimer's disease" Iranian Journal of Allergy, Asthma, and Immunology (2014)
[29]
Saikosaponin A and Its Epimers Alleviate LPS-Induced Acute Lung Injury in Mice

Donghui Peng, Yuchan Chen, Yanping Sun et al.

Molecules 10.3390/molecules28030967
[32]
NLRP1 inflammasome is activated in patients with medial temporal lobe epilepsy and contributes to neuronal pyroptosis in amygdala kindling-induced rat model

Chen-Chen Tan, Jian-Guo Zhang, Meng-Shan Tan et al.

Journal of Neuroinflammation 10.1186/s12974-014-0233-0
[33]
Astrocytes in the initiation and progression of epilepsy

Annamaria Vezzani, Teresa Ravizza, Peter Bedner et al.

Nature Reviews Neurology 10.1038/s41582-022-00727-5
[39]
Xie W. "Inhibitory effects of saikosaponin a on rat hippocampal astrocyte activation in vitro" Nan Fang Yi Ke Da Xue Bao (2008)
[42]
Genomic Analysis of Reactive Astrogliosis

Jennifer L. Zamanian, Lijun Xu, Lynette C. Foo et al.

The Journal of Neuroscience 10.1523/jneurosci.6221-11.2012
Metrics
2
Citations
45
References
Details
Published
Mar 01, 2024
Vol/Issue
103(3)
License
View
Cite This Article
Jun‐Yan Liu, Yu‐ling Shen, Jing‐yi Zhu, et al. (2024). Saikosaponin D mitigate pilocarpine‐induced astrocyte injury by regulating the NLRP3/caspase‐1 signaling pathway. Chemical Biology & Drug Design, 103(3). https://doi.org/10.1111/cbdd.14481
Related

You May Also Like

The Future of Peptide‐based Drugs

David J. Craik, David P. Fairlie · 2012

1,741 citations

Two‐ and Three‐dimensional Rings in Drugs

Matteo Aldeghi, Shipra Malhotra · 2014

334 citations

Homology modeling in drug discovery: Overview, current applications, and future perspectives

Muhammed Tilahun Muhammed, Esin Aki‐Yalcin · 2018

316 citations